LifeStance Health Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LFST in the last 30 days.
See all $LFST insider activity →Teresa DeLuca, M.D., will resign from LifeStance Health's board and committees by December 31, 2026. The company stated the resignation is not due to any disagreement. No replacement details were disclosed.
LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Teresa DeLuca, M.D., notified the LifeStance Health Group, Inc. (the “Company”) board of directors (th
LifeStance Health Group (LFST) will release its Q3 2026 earnings on Nov. 5 before market open and host a conference call at 8:30 a.m. ET. The company is a major provider of outpatient mental healthcare with over 8,500 employees across 35 states.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LFST (LifeStance Health Group, Inc.). Coverage has been balanced: 0 bullish, 4 neutral, and 0 bearish.
Recent LFST coverage spans corporate actions, financial news and earnings.
Board resignation is a modest corporate governance change with limited immediate market effect.
Board resignation may cause modest downside pressure as investors reassess governance.
This is a scheduled earnings-release setup for LFST, creating a near-term catalyst window for positioning and implied-volatility changes.
The reporting change may affect analyst coverage and investor visibility, but no immediate financial impact is evident.
Analyst target raise suggests bullish sentiment and may drive short-term buying.
AlphAI scores every news story that mentions LFST with an AI model for sentiment and relevance, and aggregates insider trades from LifeStance Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teresa DeLuca, M.D., will resign from LifeStance Health's board and committees by December 31, 2026. The company stated the resignation is not due to any disagreement. No replacement details were disclosed.
1 min readLifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Teresa DeLuca, M.D., notified the LifeStance Health Group, Inc. (the “Company”) board of directors (th
1 min readLifeStance Health Group (LFST) will release its Q3 2026 earnings on Nov. 5 before market open and host a conference call at 8:30 a.m. ET. The company is a major provider of outpatient mental healthcare with over 8,500 employees across 35 states.
2 min readLifeist Wellness Inc. (LFST) will report semi-annually, skipping Q1 and Q3 filings, while continuing six-month and annual reports. This change is not a performance update but affects financial data frequency for investors.
1 min readKeyBanc raised its price target for Lifestance Health (LFST) to $15.00 from $13.00, citing growth in specialty care and treatment-resistant depression therapies. The firm projects 30% revenue growth and expanding margins through 2030. LFST stock has surged 87% in six months, with analysts expecting profitability this year. The company recently reported strong Q2 2026 earnings, exceeding expectations and raising full-year guidance.
2 min readKeybanc maintained an Overweight rating and $15 price target for LifeStance Health Gr, implying a 26.8% upside from the Oct 2 close. The firm cited strong growth potential in specialty care, projecting revenue to rise from $70M in 2026 to $200M by 2030, driven by TMS and Spravato treatments. The company's robust patient referral system was also highlighted as a competitive advantage.
1 min readTPG GP A, LLC sold 18.41M shares of LifeStance Health Group Inc (LFST) at $12.29/share, reducing its stake by 18.77%. LFST remains 22.55% of TPG's portfolio. LFST has a $4.82B market cap, a PE ratio of 97.46, and is deemed significantly overvalued by GuruFocus. The stock has gained 82.04% YTD but is down 36.65% since its 2021 IPO.
2 min readTPG GP A, LLC sold 18,409,705 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $12.29 ($226.26M total) on 2026-09-11. Filed jointly with COULTER JAMES G (10% owner) and WINKELRIED JON (10% owner).
1 min readLifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On September 9, 2026, LifeStance Health Group, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) by and among the Company, Barclays Capital Inc. (the “ Underwriter ”), and the selling stockholders named in Schedu
1 min readZacks.com highlighted five companies with low debt-to-equity ratios: LifeStance Health (LFST) reported 26% revenue growth, Tutor Perini (TPC) won a $42M contract, News Corp (NWS) saw 11% revenue growth, Everus Construction (ECG) acquired Epsilon Industries, and HF Sinclair (DINO) finalized a pipeline joint venture. All five companies have positive earnings estimates and Zacks Rank #1 or #2.
3 min read
